NextGenNK
NextGenNK is a Competence Center for the development of next generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. The Center was launched in 2020, and is jointly funded by Vinnova, KI, and the Industrial partners.
News
Upcoming events
General Assembly 2021
General Assembly 2021
The general assembly gathered in an online meeting on September 16, 2021. The protocol is uploaded under Board and Protocols.
Executive Board meeting
Executive Board meeting
On September 16, 2021 the Executive Board of NextGenNK held its seventh meeting. The protocol is uploaded under Board and Protocols.
First patient included in phase II study in multiple myeloma
First patient included in phase II study in multiple myeloma
The first patient has been included in a phase II clinical study to treat patients with multiple myeloma using autologous NK cell-based candidate drug in combination with Sarclisa (Isatuximab).